<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Canary Speech, provider of a virtual diagnostic platform, has raised USD 13 million in a Series A funding round led by Cortes Capital, with participation from other venture capital firms. This brings the total funds raised by the company to USD 18.3 million.
      </p>
    </li>
    <li>
      <p>
        The raised funds will be used to expand the company&rsquo;s team and scale its platform.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://hitconsultant.net/2024/06/11/canary-speech-secures-13m-for-ai-powered-vocal-biomarkers/">
      HIT Consultant
    </a>
  </p>
</div>


Telehealth

<div>

 <p>Canary Speech, a virtual diagnostic platform provider, has garnered USD 13 million in a Series A funding round. The lead investor was Cortes Capital, accompanied by other venture capital firms. This funding round boosts the total capital raised by Canary Speech to USD 18.3 million.</p>
 <p>The company plans to utilize these funds to enhance team expansion and escalate the scale of its platform.</p>

</div>

Canary Speech raises USD 13 million in Series A funding

Additive manufacturing makes objects by systematically adding material via a CAD program

Additive Manufacturing

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 <p>Hexagon's Manufacturing Intelligence division, a leading provider of manufacturing technology solutions, has unveiled its latest innovation, the Advanced Compensation technology specifically designed for metal 3D printing. The novel technology is anticipated to be available to all existing Simufact Additive customers starting from the first quarter of 2025.</p>
 <p>The distinctive aspect of this technology is its potential to blend process simulation with geometry compensation which is vital in guaranteeing that large or intricate metal parts deform into their predefined shape during the printing process. The cutting-edge solution is compatible with Hexagon's Simufact Additive software and VGSTUDIO MAX technology. This integration equips users with the capability to perform actions on parts and compensate print-ready meshes with the help of 3D scan data. Based on the information provided by Hexagon, the introduction of the new technology will empower manufacturers to attain surface profiles that are between 98% and 100% within the acceptable tolerance range. Other projected benefits of the technology include reduction in material waste and a decrease in support structures.</p>
</div>

Hexagon unveils Advanced Compensation for metal 3D printing

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

ANALYST_QUICK_TAKE

<div>
 
 <p>The global introduction of the latest application, MSK-IMPACT, created with SOPHiA DDM, has been announced by SOPHiA GENETICS. This product enables companies across the globe to use the comprehensive genomic profiling (CGP) application of the Memorial Sloan Kettering Cancer Center on the SOPHiA DDM platform.</p>
 <p>By providing increased accuracy in identifying somatic mutations connected to the current pharmaceutical industry R&amp;D pipelines, MSK-IMPACT optimises oncology analyses. Its matched tumour-normal analysis approach is geared towards assisting medical practitioners to recognise somatic mutations with higher confidence and prevent confusion of germline variants as tumour-specific. It is anticipated that this recent launch will make advanced tumour profiling technology more widely accessible internationally.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> The SOPHiA DDM platform received the CE marking under the EU's In Vitro Diagnostic Regulation in <a href="https:<br>
//sp-edge.com/updates/32655"> August 2024 </a> , a key regulatory requirement when expanding to international markets, including the EU and other markets recognizing this certification. The platform reportedly includes five existing CE-IVD applications and a global network of partners for collective intelligence.</p>

SOPHiA GENETICS announces global launch of MSK-IMPACT powered with SOPHiA DDM

<div>
 
 <p>Biofidelity has initiated the Aspyre Clinical Test for Lung, a genomic evaluation test targeting non-small-cell lung cancer genes from tissue and blood specimens. This test is now active for clinical practice through their lab services.</p>
 <p>The Aspyre test identifies somatic mutations from DNA and gene unions directly from RNA in tissue and blood specimens. This test offers results in two days, scans all suggested genes for non-small-cell lung cancer patients, and can handle challenging specimens.</p>
 <p>The company states that the major advantages of the test are next-day turnaround time, compatibility with both tissue and blood specimens, and eradication of the requirement for distinct tests, consequently reducing further sample requirements and costs. The firm aims to reveal supporting clinical performance statistics at the International Society of Liquid Biopsy Annual Meeting 2024.</p>
 
</div> <p><b>Analyst QuickTake:<br>
</b> In <a href="https:<br>
//sp-edge.com/updates/28192"> April 2024 </a> , Biofidelity raised USD 24 million in venture funding to fast-track the adoption of the ASPYRE-Lung test for NSCLC. The funds were also directed toward supporting commercial and clinical expansion in the US, establishing a manufacturing facility in the UK, and enhancing its existing technology platforms.</p>

Biofidelity launches Aspyre Clinical Test for lung cancer detection

Platforms, apps, and cards to keep the corporate wallet in check

Business Expense Management

<div>
 <p>Spendesk, a spend management platform, has joined forces with Adyen, a fintech platform, to capitalize on Adyen's banking-as-a-service capabilities across several markets. The collaboration will utilize Adyen's banking licenses in the UK, US, and EU, giving Spendesk the opportunity to amplify its payment solution offerings. These include digital wallets, streamlined client onboarding, and boosted payment processing.</p>
 <p>The partnership is part of Spendesk's 2025 plan to speed up new product developments while ensuring regulatory compliance in its areas of operation. The ultimate goal is to revamp spend management workflows for small and medium-sized businesses (SMBs). This will be achieved by increasing visibility in the payment process, adding flexible payment options, and enhancing operational efficiency.</p>
</div> <p><b>Analyst QuickTake</b> :<br>
 This partnership builds on Spendesk's recent launch of its procurement and spend management tool for European SMBs in <a href="https:<br>
//sp-edge.com/updates/35131"> October 2024. </a> Adyen is based in the Netherlands and holds banking licenses across Europe, so the collaboration is expected to support Spendesk in expanding its operations and activities within the region.</p>

Spendesk partners with Adyen to enhance SMB spend management with banking-as-a-service solution

Travel Tech

<div>
 <p>Mews, a hospitality platform provider, recently purchased Atomize, a software company based in Sweden that specializes in revenue management. The intention behind this acquisition is to augment the features of the Mews cloud-based system for hospitality. This will happen through the inclusion of Atomize's capabilities to provide market data and predictive insights, thus allowing those in the hotel industry to make decisions based on real-time information and to enhance revenue-earning potential in a more effective manner.</p>
 <p>Established in 2016, Atomize offers solutions in hotel prediction and real-time dynamic pricing. With a focus on turning complex market information into applicable insights, its platform is used in over 50 countries across five continents. The range of properties it serves spans from hotels with a capacity of 50 rooms to those that can accommodate 1,250 guests.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> Mews has adopted a strategic acquisition approach to expand its geographic presence and diversify its product portfolio. In <a href="https:<br>
//sp-edge.com/updates/35658"> November 2024, </a> the company acquired Quotelo, a French event management platform, to enhance its R&amp;D capabilities. In <a href="https:<br>
//sp-edge.com/updates/29443"> May 2024, </a> Mews strengthened its presence in Germany by acquiring HS3 Hotelsoftware.</p>

Mews acquires Swedish RMS provider Atomize to enhance Hospitality Cloud platform

<div>
 <p>The company Lighthouse, previously OTA Insights, has raised USD 370 million in a Series C funding round headed by KKR. Existing investors, including Spectrum Equity, F-Prime Capital, Eight Roads Ventures, and Highgate Technology Ventures, will remain involved. This funding will boost product innovation on Lighthouse's platform, enable strategic acquisitions and promote their efforts for global expansion. The company aims to improve its commercial platform through increased AI capabilities and additional datasets.</p>
</div>

Lighthouse raises USD 370 million in Series C funding to drive growth

Novel therapies to reboot cells and organs

Cell & Gene Therapy

<div>
 <p>Pharmaceutical company Novartis has purchased AAV-based gene therapy developer Kate Therapeutics for a potential total of USD 1.1 billion. This is inclusive of an initial payment and the prospect of additional milestone payments.</p>
 <p>Kate Therapeutics' primary focus is on gene therapy development for neuromuscular illnesses. Their primary research includes candidates in preclinical trials for Duchenne muscular dystrophy (DMD), facioscapulohumeral dystrophy (FSHD), and myotonic dystrophy type one (DM1). In aid of this, they have developed the DELIVER platform which allows for the production of liver-de-targeted muscle-tropic capsids, a tool that can improve gene therapy delivery.</p>
 <p>By acquiring Kate Therapeutics, Novartis intends to strengthen its footprint in gene therapy and neuroscience innovation. The goal is to use Kate Therapeutics' technology to develop new treatment possibilities for patients suffering from inherited neuromuscular diseases.</p>
 
</div> <p><b>Analyst QuickTake</b> :<br>
 Kate Therapeutics joins the gene therapy-related acquisitions Novartis has undertaken. In May 2023, the pharma giant acquired a hematopoietic stem cell gene therapy program for treating the rare genetic condition cystinosis from <a href="https:<br>
//www.pharmexec.com/view/novartis-acquires-avrobio-s-88m-gene-therapy"> Avrobio </a> for USD 87.5 million, in addition to acquiring <a href="https:<br>
//www.fiercebiotech.com/biotech/novartis-inks-800m-upfront-buyout-gyroscope-to-continue-eye-disease-gene-therapy-m-a-spree"> Gyroscope Therapeutics </a> in December 2021.</p>

Novartis acquires Kate Therapeutics for USD 1.1 billion to expand neuromuscular gene therapy portfolio

Foundation Models

<div>
 
 <p>OpenAI has released an update called "gpt-4o-2024-11-20" for its language model, GPT-4o. The company reports that this update heightens the model's creative writing features, consequential file handling for deeper understanding, and comprehensive responses. Additionally, it presents a 128k context window.</p>
 <p>The upgraded model topped the LLM benchmark on lmarena.ai and exhibited enhanced code editing abilities on Aider's benchmark. OpenAI mentions that the improved GPT-4o outperforms GPT-4 Turbo in complex and multi-step tasks and it's more cost-efficient. Some users have noted the model's ability to evade standard AI text detector tools.</p>

</div>

OpenAI releases GPT-4o update with enhanced file handling capabilities

<div>
 
 <p>H2O.ai has introduced h2oGPTe, a platform that merges generative and predictive AI models. H2oGPTe uses H2O.ai's AI models, namely Mississippi and Danube, and is compatible with other language models.</p> 
 <p>The platform is multi-functional; it can interpret charts, generate PDF documents with visualisations, and provide data traceability with source citations. Rug features include adjustable guardrails, automated question generation for model testing, and a tracking dashboard for agent activities.</p>

</div> <p><b>Analyst QuickTake:<br>
 </b> This follows the launch of <a href="https:<br>
//sp-edge.com/updates/31838"> the H2O-Danube3 </a> series with advanced capabilities in July this year. The introduction of Agentic AI is particularly noteworthy as it addresses the growing demand for more intelligent and adaptable AI systems capable of making informed decisions based on predictive analytics while generating creative outputs. This dual capability allows businesses to enhance operational efficiency and improve customer engagement through tailored solutions that predict trends and generate relevant content.</p>

H2O.ai launches h2oGPTe multi-agent AI platform

Technology providers that enhance satellite operations

Next-gen Satellites

<div>
 <p>Gilmour Space Technologies has been chosen by Earth observation firm LatConnect 60 for a demonstration mission. The purpose of this mission is to offer insights into methane and carbon emissions from space. The mission will be facilitated through Gilmour's ElaraSat bus.</p>
 <p>The short-wave infrared imagery satellite (SWIRSAT) for the operation is 100 kg and will use Gilmour Space’s ElaraSat bus, compounded with Spiral Blue’s sensors and Edge computer, located at the ASMN facility in Queensland. The satellite will return high-resolution Earth observation data which will aid in achieving emissions reduction objectives. The expected launch partner is Skyroot Aerospace in India.</p>
 <p>WIRSAT holds the potential to provide key insights from extremely high-resolution Earth observation data in the short-wave infrared range. This will make it possible to precisely identify and measure source-level carbon emissions and fill a crucial data gap from low-Earth orbit.</p>
 
</div>

All Updates

Canary Speech raises USD 13 million in Series A funding

Hexagon unveils Advanced Compensation for metal 3D printing

SOPHiA GENETICS announces global launch of MSK-IMPACT powered with SOPHiA DDM

Biofidelity launches Aspyre Clinical Test for lung cancer detection

Spendesk partners with Adyen to enhance SMB spend management with banking-as-a-service solution

Mews acquires Swedish RMS provider Atomize to enhance Hospitality Cloud platform

Lighthouse raises USD 370 million in Series C funding to drive growth

Novartis acquires Kate Therapeutics for USD 1.1 billion to expand neuromuscular gene therapy portfolio

OpenAI releases GPT-4o update with enhanced file handling capabilities

H2O.ai launches h2oGPTe multi-agent AI platform

Gilmour Space partners with LatConnect 60 to build Earth observation satellite

Telehealth

Canary Speech raises USD 13 million in Series A funding

Contact us